Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 34

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 34
---
requirements of the Exchange Act applicable to foreign private issuers. We, as a “foreign private issuer,” are exempt from
the rules under the Exchange Act prescribing certain disclosure and procedural requirements for proxy solicitations, and our officers,
directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions contained
in Section 16 of the Exchange Act, with respect to their purchases and sales of shares. In addition, we are not required to file annual,
quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are
registered under the Exchange Act.

You can review our SEC filings
and the registration statement by accessing the SEC’s internet site at http://www.sec.gov. We maintain a corporate website at https://www.clearmindmedicine.com/.
Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included
our website address in this prospectus solely as an inactive textual reference.

<div align='center'>S-18</div>

PROSPECTUS

<div align='center'>Clearmind Medicine Inc.

$50,000,000

Common Shares

Subscription Rights

Warrants

Units</div>

We may offer, issue and sell
from time to time up to US $50,000,000 of our Common Shares, subscription rights, or “Subscription Rights,” warrants, or “Warrants,”
and a combination of such securities, separately or as units, or “Units”, in one or more offerings.

We refer to the Common Shares, Subscription Rights, Warrants and Units, collectively, as the “securities” in this prospectus. We may offer, issue and sell the securities at an aggregate public offering price that will not exceed 50,000,000.

Each time we sell securities pursuant to this prospectus, we will provide in a supplement to this prospectus the price and any other material terms of any such offering. Any prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement, as well as the documents incorporated by reference or deemed incorporated by reference into this prospectus, carefully before you invest in any securities. This prospectus may not be used to offer or sell securities unless accompanied by a prospectus supplement.

We may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters, agents or dealers,